MED — Medifast, Inc.

Medifast, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $76 million, down 34.3% year-over-year, marking a slight sequential growth compared to Q4 2025.
• Active Coaches: Approximately 14,000, a decrease of 44.9% from 2025.
• Revenue per Active Coach: Increased to $5,432, a 19.2% year-over-year increase, indicating improved coach productivity.
• Gross Profit: $51.8 million, down 38.6% year-over-year; gross profit margin at 68.1%, down from 72.8%.
• Loss from Operations: $3.3 million, an increase in losses compared to the previous year.
• Net Loss: $2.1 million or $0.19 per share, compared to a net loss of $800,000 or $0.07 per share in the prior year.
• Cash Position: $168.9 million in cash and investments, with no debt.

2. Strategic Updates and Business Highlights

• Medifast is transitioning its focus to the metabolic health market, reframing its weight loss approach to address broader metabolic dysfunction.
• The company has launched a new 3.0 strategy, enhancing its clinical foundation and realigning its cost structure, expected to yield $30 million in future savings.
• Coach productivity has shown significant improvement, with a 19% year-over-year increase and a 16% sequential increase, indicating higher engagement and effectiveness.
• A new comprehensive metabolic system is set to launch at the upcoming coach convention in July, featuring clinically studied products aimed at improving metabolic health.

3. Forward Guidance and Outlook

• Q2 2026 Revenue Guidance: Expected to range from $60 million to $80 million, with a loss per share between $0.50 and $1.00.
• Full-Year 2026 Revenue Guidance: Expected to range from $270 million to $300 million, with a loss per share between $1.05 and $2.75.
• Improvements towards profitability are anticipated to begin in Q4 2026, with a focus on the new product line launch.

4. Bad News, Challenges, or Points of Concern

• The decline in the number of active earning coaches continues to be a significant concern, exacerbated by the rapid adoption of GLP-1 medications affecting the traditional weight loss market.
• Revenue growth has historically lagged behind improvements in coach productivity, raising concerns about the sustainability of future revenue increases.
• The company is navigating a challenging competitive landscape with shifting consumer preferences towards GLP-1 medications, which may impact traditional weight loss strategies.

5. Notable Q&A Insights

• Management emphasized that the $30 million in cost savings will primarily come from adjustments in SG&A and COGS, with expectations for improved gross margins in the second half of the year.
• Newer coaches are driving productivity, as they are more attuned to the current market dynamics influenced by GLP-1 medications.
• The company is focused on messaging the quality of weight loss, highlighting the importance of metabolic health over mere weight reduction.
• The CEO, Daniel R. Chard, announced his impending departure effective June 1, 2026, transitioning to the role of chairman, which may raise questions about leadership continuity during this strategic shift.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Medifast's current position and outlook.